CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 652 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03159195
NCT03159195N/ACompleted

TREATMENT PATTERNS AND CLINICAL OUTCOMES AMONG PATIENTS RECEIVING PALBOCICLIB COMBINATIONS FOR HR+/HER2- ADVANCED/METASTATIC BREAST CANCER IN REAL WORLD SETTINGS

Pfizer·observational·Posted May 18, 2017·Updated Jul 1, 2025

In Brief

An observational study for Malignant Neoplasm of Breast. Completed, enrolled 652 participants across 1 site.

Detailed Summary

To describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments in line with regional licensed indications in real world settings across multiple countries.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedMay 18, 2017
Enrollment StartJun 12, 2017
Primary CompletionJul 23, 2020
Study CompletionJun 24, 2021
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 9.1 years ago